Anaplastic astrocytoma

Anaplastic Astrocytoma Market Forecast to 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Anaplastic Astrocytoma - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anaplastic Astrocytoma - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Anaplastic Astrocytoma- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anaplastic Astrocytoma, historical and forecasted epidemiology as well as the Anaplastic Astrocytoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The report covers the descriptive overview of Anaplastic Astrocytoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
    Additionally, an all-inclusive account of both the current and emerging therapies for Anaplastic Astrocytoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
    A detailed review of Anaplastic Astrocytoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
    The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaplastic Astrocytoma market
    In the coming years, Anaplastic Astrocytoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
    The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic Astrocytoma R&D.
  • The therapies under development are focused on novel approaches to treat/improve the disease condition
    Major players are involved in developing therapies for Anaplastic Astrocytoma.

Global Brain Tumor Drugs Market (2022 to 2031) - Featuring Pfizer, Shimadzu and Celgene Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 7, 2022

The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.

Key Points: 
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib.
  • The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide.
  • Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market.

Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

Retrieved on: 
Wednesday, January 19, 2022

PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete. The STELLAR study completed full enrollment with a total of 343 patients.

Key Points: 
  • PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete.
  • The STELLAR study completed full enrollment with a total of 343 patients.
  • We are delighted to announce that we have completed enrollment of patients in the STELLAR study.
  • The STELLAR study is the largest randomized Phase 3 study that has been conducted in this patient population, said Bob Myers, co-founder and CEO.

Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine

Retrieved on: 
Tuesday, September 28, 2021

PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No. 3432872 entitled “Compositions and Methods for Use of Eflornithine and Derivatives and Analogs thereof to Treat Cancers, Including Gliomas,” by the European Patent Office (EPO).

Key Points: 
  • - Patent relates to method for use of eflornithine to treat cancers, including gliomas -
    PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No.
  • 3432872 entitled Compositions and Methods for Use of Eflornithine and Derivatives and Analogs thereof to Treat Cancers, Including Gliomas, by the European Patent Office (EPO).
  • The patent, which was granted on August 25, 2021 and is being validated in 15 European countries including Germany, France, Spain, the United Kingdom and Italy, covers eflornithine or a pharmaceutically acceptable salt thereof in a method for the treatment of temozolomide-recurrent anaplastic astrocytoma.
  • Orbus Therapeutics Inc. is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies.

TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 million

Retrieved on: 
Friday, August 13, 2021

HONG KONG, Aug 13, 2021 - (ACN Newswire) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Group"; stock code: 1875.HK), a biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its unaudited interim results for the six months ended 30 June 2021.

Key Points: 
  • HONG KONG, Aug 13, 2021 - (ACN Newswire) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Group"; stock code: 1875.HK), a biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its unaudited interim results for the six months ended 30 June 2021.
  • TOZ309 is the first self-developed chemical drug of TOT BIOPHARM.
  • -- In the first half of 2021, TOT BIOPHARM actively deployed for ADC pilot production and commercial production.
  • TOT BIOPHARM has developed three core business advantages, providing a solid foundation for development of and cooperation in relation to innovative drugs.

Author Shares Message of Hope in Wake of a Loved One’s Death in Debut Book

Retrieved on: 
Monday, January 11, 2021

Many people enjoy blessings like family, health, and prosperity; however, they inevitably will also suffer loss, hardship, and grief.

Key Points: 
  • Many people enjoy blessings like family, health, and prosperity; however, they inevitably will also suffer loss, hardship, and grief.
  • In 2012, Borrows LaRues life was turned upside-down after her husband, Daryle, was diagnosed with anaplastic astrocytoma a rare and malignant brain cancer.
  • Leading up to and following his death one year later to the day, Borrows LaRue turned to her faith and found strength and hope through her relationship with God.
  • It was only because of the Lords prompting and gentle nudging that this book has come to be.

Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations

Retrieved on: 
Wednesday, December 23, 2020

10,786,470 entitled Formulations for Administration of Eflornithine, by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • 10,786,470 entitled Formulations for Administration of Eflornithine, by the United States Patent and Trademark Office (USPTO).
  • The patent, which was granted on September 29, 2020, covers a solution of eflornithine hydrochloride hydrate for oral administration and methods of use for treating gliomas including anaplastic astrocytoma.
  • Orbus is currently evaluating eflornithine in an ongoing Phase 3 clinical trial, the STELLAR study, in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant chemotherapy.
  • Orbus Therapeutics is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies.

Study Shows Typical Cancer-Free Survival Doubled for Recurrent Brain Cancer Patients when KIYATEC’s Test Informed Therapy Selection

Retrieved on: 
Thursday, December 17, 2020

today announced the first clinical use of its response-prediction test to improve outcomes in relapsed brain cancer patients.

Key Points: 
  • today announced the first clinical use of its response-prediction test to improve outcomes in relapsed brain cancer patients.
  • A case series of seven patients with recurrent high-grade gliomas six with glioblastoma multiforme (GBM) and one with anaplastic astrocytoma was detailed.
  • The use of KIYATECs test results to inform drug selection approximately doubled the typical expectation, achieving a group median PFS of 7.9 months, a significant improvement over expected PFS in these patients.
  • KIYATECs test results informed two of the seven patients successful treatment with dabrafenib, a targeted agent.

Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer

Retrieved on: 
Thursday, October 22, 2020

As part of this expanded financing, Abingworth LLP has joined the existing Series A investors led by Longitude Capital, H.I.G.

Key Points: 
  • As part of this expanded financing, Abingworth LLP has joined the existing Series A investors led by Longitude Capital, H.I.G.
  • The expanded Series A funding will support the ongoing STELLAR study, a Phase 3 clinical trial studying eflornithine in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant chemotherapy.
  • Orbus is also planning to initiate additional clinical studies to study eflornithine in patients suffering from other forms of malignant gliomas.
  • In total, the expanded Series A represents funding of $71 million, which includes an initial financing of $32.5 million in 2015.

Global Adult Malignant Glioma Therapeutics Market Research Report 2019-2024: Merck & Co, Roche, and Pfizer Lead the Competition

Retrieved on: 
Friday, July 12, 2019

DUBLIN, July 12, 2019 /PRNewswire/ -- The "Adult Malignant Glioma Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 12, 2019 /PRNewswire/ -- The "Adult Malignant Glioma Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • North America and Europe are projected to dominate the global adult malignant glioma therapeutics market during the forecast period, primarily due to the significant reimbursement coverage.
  • In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others.
  • The major players operating in the market include Merck & Co. Inc., F. Hoffmann-La Roche Ltd, and Pfizer, Inc. among others.